Dr. Thomas W. McLean
Claim this profileWake Forest University Health Sciences
About Thomas W. McLean
Education:
- Obtained MD from Wake Forest University School of Medicine in 2008.
- Completed Residency in Internal Medicine at Wake Forest Baptist Medical Center in 2011.
- Finished Fellowship in Hematology and Oncology at Wake Forest Baptist Medical Center in 2014.
Experience:
- Currently serves as an Assistant Professor of Hematology and Oncology at Wake Forest School of Medicine.
Area of expertise
Brain Tumor
Thomas W. McLean has run 12 trials for Brain Tumor. Some of their research focus areas include:
Cancer
Thomas W. McLean has run 10 trials for Cancer. Some of their research focus areas include:
Affiliated Hospitals
Wake Forest University Health Sciences
Clinical Trials Thomas W. McLean is currently running
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting
2 awards
Phase 3
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting
2 awards
Phase 3
More about Thomas W. McLean
Clinical Trial Related
6 years of experience running clinical trials · Led 44 trials as a Principal Investigator · 22 Active Clinical Trials
Treatments Thomas W. McLean has experience with
- Cyclophosphamide
- Radiation Therapy
- Etoposide
- Doxorubicin Hydrochloride
- Methotrexate
- Vincristine Sulfate
Breakdown of trials Thomas W. McLean has run
Brain Tumor
Cancer
Neuroblastoma
Brain Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Thomas W. McLean specialize in?
Thomas W. McLean focuses on Brain Tumor and Cancer. In particular, much of their work with Brain Tumor has involved Stage I patients, or patients who are Stage II.
Is Thomas W. McLean currently recruiting for clinical trials?
Yes, Thomas W. McLean is currently recruiting for 22 clinical trials in Winston-Salem North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Thomas W. McLean has studied deeply?
Yes, Thomas W. McLean has studied treatments such as Cyclophosphamide, Radiation Therapy, Etoposide.
What is the best way to schedule an appointment with Thomas W. McLean?
Apply for one of the trials that Thomas W. McLean is conducting.
What is the office address of Thomas W. McLean?
The office of Thomas W. McLean is located at: Wake Forest University Health Sciences, Winston-Salem, North Carolina 27157 United States. This is the address for their practice at the Wake Forest University Health Sciences.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.